Organogenesis cuts 2026 revenue outlook after steep quarterly sales decline

Organogenesis Holdings Inc. reported second quarter 2026 results on August 6, 2026, showing net revenue of $42.8 million for the second quarter of 2026, a decrease of $58.0 million compared to net revenue of $100.8 million for the second quarter of 2025.¹ The decline was driven largely by Advanced Wound Care, where net revenue from Advanced Wound Care products was $36.1 million, a decrease of 61% from the second quarter of 2025.¹

CEO Gary S. Gillheeney, Sr. said "We are encouraged by signs of measured improvement in business trends in the second quarter, though the pace of recovery from the significant market contraction is slower than we expected."¹ He added that the company is "advancing the ReNu program to unlock new markets for the company."¹

The company lowered its full-year outlook, now expecting total net revenue between $179.0 million and $215.0 million, representing a decline in the range of 62% to 68%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025.¹ The updated guidance assumes sequential improvement in revenue trends in the third and fourth quarters, but at a more measured rate versus prior guidance, resulting in a second half revenue decline in the range of approximately 64% to 74% year over year, compared to the prior guidance range of 45% to 52% year-over-year decline.¹

Net loss widened sharply, reaching $96.3 million for the second quarter of 2026, compared to a net loss of $9.4 million for the second quarter of 2025.¹ Cash also declined, with the company reporting $46.8 million in cash, cash equivalents and restricted cash and no outstanding debt obligations as of June 30, 2026, compared to $94.3 million as of December 31, 2025.¹

Among the factors cited in forward-looking risk disclosures is whether the Company is able to obtain regulatory approval for and successfully commercialize ReNu.¹